JP2005511754A - 乳癌幹細胞の予測的同定および特徴づけ - Google Patents

乳癌幹細胞の予測的同定および特徴づけ Download PDF

Info

Publication number
JP2005511754A
JP2005511754A JP2003551505A JP2003551505A JP2005511754A JP 2005511754 A JP2005511754 A JP 2005511754A JP 2003551505 A JP2003551505 A JP 2003551505A JP 2003551505 A JP2003551505 A JP 2003551505A JP 2005511754 A JP2005511754 A JP 2005511754A
Authority
JP
Japan
Prior art keywords
cells
solid tumor
stem cells
tumor stem
tumorigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003551505A
Other languages
English (en)
Japanese (ja)
Inventor
マイケル エフ． クラーク
マックス エス． ウィチャ
モハマド アル−ハッジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of JP2005511754A publication Critical patent/JP2005511754A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
JP2003551505A 2001-12-07 2002-12-06 乳癌幹細胞の予測的同定および特徴づけ Withdrawn JP2005511754A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33835801P 2001-12-07 2001-12-07
PCT/US2002/039191 WO2003050502A2 (fr) 2001-12-07 2002-12-06 Identification et caracterisation prospectives des cellules souches cancereuses du sein

Publications (1)

Publication Number Publication Date
JP2005511754A true JP2005511754A (ja) 2005-04-28

Family

ID=23324500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003551505A Withdrawn JP2005511754A (ja) 2001-12-07 2002-12-06 乳癌幹細胞の予測的同定および特徴づけ

Country Status (6)

Country Link
US (1) US20050089518A1 (fr)
EP (1) EP1461023A4 (fr)
JP (1) JP2005511754A (fr)
AU (1) AU2002364537A1 (fr)
CA (1) CA2469204A1 (fr)
WO (1) WO2003050502A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006349658A (ja) * 2005-02-21 2006-12-28 Hisamitsu Pharmaceut Co Inc 神経系癌幹細胞の検出試薬、神経系癌幹細胞を分離する方法、神経系癌幹細胞、及び神経芽腫の予後診断薬。
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
JP2010504755A (ja) * 2006-09-29 2010-02-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
WO2016167306A1 (fr) * 2015-04-16 2016-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 ANTICORPS ANTI-Notch 4 HUMAIN
US9480744B2 (en) 2010-09-10 2016-11-01 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9511139B2 (en) 2009-10-16 2016-12-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US11046760B2 (en) 2014-10-31 2021-06-29 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2528669A1 (fr) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions et methodes de traitement et de diagnostic du cancer
ES2383306T3 (es) * 2004-02-03 2012-06-20 The Regents Of The University Of Michigan Composiciones para el tratamiento del cáncer de mama y de páncreas
WO2005074633A2 (fr) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions et procédés permettant de caractériser, de réguler, de diagnostiquer et de traiter des cancers
EP1732549A4 (fr) * 2004-03-18 2009-11-11 Brigham & Womens Hospital Procedes pour le traitement de synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559221A1 (fr) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
KR100868316B1 (ko) * 2005-04-20 2008-11-11 재단법인서울대학교산학협력재단 유방 조직에서 유래된 줄기 세포, 이의 제조방법 및이로부터 분화된 세포
JP5405824B2 (ja) * 2005-06-30 2014-02-05 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 前駆細胞及びその使用
US20070220621A1 (en) * 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
AU2006344359B2 (en) 2005-10-31 2013-08-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CA2630839C (fr) * 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Procedes therapeutiques pour l'inhibition de croissance tumorale avec des antagonistes dll4
WO2008121102A2 (fr) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Traitement du cancer par un antagoniste de la voie de signalisation hedgehog
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2007109193A2 (fr) * 2006-03-16 2007-09-27 Health Research Inc. Inhibition de la croissance et de la métastase de cellules souches du cancer du sein
WO2007142987A2 (fr) * 2006-05-30 2007-12-13 Wisconsin Alumni Research Foundation Marqueur de cellules souches mammaires
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
EP2783700A1 (fr) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Thérapie du cancer ciblant des cellules souches cancéreuses
JP2010502210A (ja) * 2006-09-07 2010-01-28 ウニベルシダド・デ・サラマンカ 遺伝子マーカーを使用する癌幹細胞の同定
US20080187938A1 (en) 2006-09-22 2008-08-07 The Regents Of The University Of Michigan ALDH1 As A Cancer Stem Cell Marker
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
EP2106439B1 (fr) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
KR20090089120A (ko) * 2008-02-18 2009-08-21 재단법인서울대학교산학협력재단 다능성 암 줄기 세포주 및 이의 제조방법
SI2307051T1 (sl) 2008-07-08 2015-04-30 Oncomed Pharmaceuticals, Inc. Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010037041A2 (fr) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
DK2356462T3 (en) 2008-11-11 2017-02-27 Univ Michigan Regents ANTI-CXCR1 COMPOSITIONS AND PROCEDURES
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
JP2013512278A (ja) * 2009-12-01 2013-04-11 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｋ−ｒａｓ変異を含んだ癌を処置するための方法
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011088215A2 (fr) 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Agents de liaison notch1 et leurs procédés d'utilisation
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
NZ704269A (en) 2012-07-13 2016-05-27 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
CA3102264A1 (fr) 2018-06-19 2019-12-26 Lunella Biotech, Inc. Cellules souches cancereuses « energetiques » (e-csc) : un nouveau phenotype de cellule tumorale hyper-metabolique et proliferative, mu par l'energie mitochondriale

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411990A (en) * 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5994617A (en) * 1988-09-19 1999-11-30 Hsc Research Development Corporation Engraftment of immune-deficient mice with human cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en) * 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6353150B1 (en) * 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) * 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5928947A (en) * 1992-07-27 1999-07-27 California Institute Of Technology Mammalian multipotent neural stem cells
US5589376A (en) * 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
AU678988B2 (en) * 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
US5654183A (en) * 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
US5650317A (en) * 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5821108A (en) * 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
CA2263883C (fr) * 1996-08-29 2003-07-08 The Regents Of The University Of California Kuz, nouvelle famille de metalloproteases
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
WO1998057621A1 (fr) * 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Modulation angiogenique par transduction du signal de notch
US6136952A (en) * 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6197523B1 (en) * 1997-11-24 2001-03-06 Robert A. Levine Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood
US6380362B1 (en) * 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
EP2388330B1 (fr) * 2001-06-22 2015-05-20 StemCells, Inc. Cellules de greffe hépatique, dosages, et leurs utilisations

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006349658A (ja) * 2005-02-21 2006-12-28 Hisamitsu Pharmaceut Co Inc 神経系癌幹細胞の検出試薬、神経系癌幹細胞を分離する方法、神経系癌幹細胞、及び神経芽腫の予後診断薬。
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
JP2010504755A (ja) * 2006-09-29 2010-02-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
JP2014158469A (ja) * 2006-09-29 2014-09-04 Oncomed Pharmaceutical Inc 癌の診断および処置のための組成物および方法
KR101477824B1 (ko) * 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. 암의 진단 및 치료를 위한 조성물 및 방법
US9228020B2 (en) 2006-09-29 2016-01-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2017002076A (ja) * 2006-09-29 2017-01-05 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US9376497B2 (en) 2006-09-29 2016-06-28 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9511139B2 (en) 2009-10-16 2016-12-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent
US9480744B2 (en) 2010-09-10 2016-11-01 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US9376488B2 (en) 2011-09-23 2016-06-28 Oncomed Pharmaceuticals, Inc. VEGF binding antibodies
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US11046760B2 (en) 2014-10-31 2021-06-29 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016167306A1 (fr) * 2015-04-16 2016-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 ANTICORPS ANTI-Notch 4 HUMAIN
US9527921B2 (en) 2015-04-16 2016-12-27 Eisai R&D Management Co., Ltd. Anti human Notch4 antibody
JPWO2016167306A1 (ja) * 2015-04-16 2018-02-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトＮｏｔｃｈ４抗体
US9969812B2 (en) 2015-04-16 2018-05-15 Eisai R&D Management Co., Ltd. Anti human Notch4 antibody

Also Published As

Publication number Publication date
WO2003050502A2 (fr) 2003-06-19
CA2469204A1 (fr) 2003-06-19
US20050089518A1 (en) 2005-04-28
WO2003050502A9 (fr) 2004-05-06
WO2003050502A3 (fr) 2004-02-12
EP1461023A2 (fr) 2004-09-29
AU2002364537A1 (en) 2003-06-23
EP1461023A4 (fr) 2005-08-31

Similar Documents

Publication Publication Date Title
JP2005511754A (ja) 乳癌幹細胞の予測的同定および特徴づけ
US10940180B2 (en) Method for identifying, expanding, and removing adult stem cells and cancer stem cells
Dogan et al. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue.
Melamed et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor
Huang et al. Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases
Li et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target
Tai et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells
Lozupone et al. Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice
Zhang et al. A subpopulation of CD133+ cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy
Chapiro et al. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer
EP2764874A1 (fr) Procédés pour identifier et enrichir des populations de cellules souches cancéreuses ovariennes et cellules souches somatiques et leurs utilisations
US7833789B2 (en) Monocyte cell
JP2007526455A (ja) 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
Barbieri et al. Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential
Tripathi et al. Heparanase promotes myeloma stemness and in vivo tumorigenesis
KR20110073534A (ko) 전립선 줄기 세포 및 그의 용도
GB2442059A (en) Test for cancer of the gastrointestinal tract
US6998513B1 (en) Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use
CA2916394A1 (fr) Modele de cancer colorectal
Woodward et al. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials
JP6664685B2 (ja) 抗がん剤
US7223596B2 (en) Malignant endothelial cell line and uses thereof in models for angiogenesis
Makela et al. Targeted intracellular delivery to hypoxic human breast cancer stem cells
Shahoei The immunomodulatory roles of small heterodimer partner and their implications in breast cancer progression
Prasit Harnessing iNKT cells to improve in situ vaccination for cancer therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070627